Efficient Dlx2-mediated astrocyte-to-neuron conversion and inhibition of neuroinflammation by NeuroD1
簡介:
- 作者: Min-Hui Liu, Yu-Ge Xu, Xiao-Ni Bai, Jian-Hua Lin, Zong-Qin Xiang, Tao Wang, Liang Xu, Wen Li, Gong Chen
- 雜志: BioRxiv
- Doi: https://www.doi.org/10.1101/2022.07
- 出版日期: 2022 Jul 12
論文中使用的產品/服務
Quotation shows PackGene:hGFAP promoter used in the AAV vectors is the synthetic 681- bp gfaABC1D. The construction of pAAV GFAP::GFP, GFAP::Dlx2-P2A-GFP, GFAP::NeuroD1-P2A-GFP, the following AAV9 virus package, purification with iodixanol and subsequent concentration, as well as virus titration were produced by PackGene? Biotech, LLC (Guangzhou, China).
Research Field:CNS
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:Both adult male and female wild-type C57BL/6J mice (Guangdong Medical Laboratory Animal Center) and Aldh1l1::CreERT2 transgenic mice (The Jackson Laboratory, RRID:IMSR_JAX:031008) at 2-5 months of age were recruited in the experiments.
摘要
In vivo astrocyte-to-neuron (AtN) conversion induced by overexpression of neural transcriptional factors has great potential for neural regeneration and repair. Here, we demonstrate that a single neural transcriptional factor Dlx2 converts mouse striatal astrocytes into neurons in a dose-dependent manner. Lineage-tracing studies in Aldh1l1-CreERT2 mice confirm that Dlx2 can convert striatal astrocytes into DARPP32+ and Ctip2+ medium spiny neurons (MSNs). Time-course studies reveal a gradual conversion from astrocytes to neurons in 1 month, with a distinct intermediate state in-between astrocytes and neurons. Interestingly, when Dlx2-infected astrocytes start to lose astrocytic markers, the other local astrocytes proliferate to maintain astrocytic level in the converted areas. Unexpectedly, while Dlx2 efficiently reprograms astrocytes into neurons in the grey matter striatum, it also induces partial reprogramming of astrocytes in the white matter corpus callosum. Such partial reprogramming of white matter astrocytes is associated with neuroinflammation, which can be essentially suppressed by the addition of NeuroD1. Our results highlight the importance of investigating AtN conversion both in the grey matter and white matter in order to thoroughly evaluate therapeutic potentials. This study also unveils a critical role of anti-inflammation by NeuroD1 during AtN conversion.
關于派真
作為一家專注于AAV 技術十余年,深耕基因治療領域的CRO&CDMO,派真生物可提供從載體設計、構建到 AAV、慢病毒和 mRNA 服務的一站式解決方案。憑借深厚的技術實力、卓越的運營管理和高標準的服務交付,我們?yōu)槿蚩蛻籼峁┮徽臼?/span>CMC解決方案,包括從早期概念驗證、成藥性評估到IIT、IND及BLA的各個階段。
?
憑借我們獨立知識產權的π-alphaTM 293 細胞AAV高產技術平臺,我們能將AAV產量提高多至10倍,每批次產量可達1×101?vg,以滿足多樣化的商業(yè)化和臨床項目需求。此外,我們定制化的mRNA和脂質納米顆粒(LNP)產品及服務覆蓋藥物和疫苗開發(fā)的各個階段,從研發(fā)到符合GMP的生產,提供端到端的一站式解決方案。